Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy

N. Margolis, E. Markovits, Gal Markel*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

This decade has introduced drastic changes in melanoma therapy, predominantly due to the materialization of the long promise of immunotherapy. Cytotoxic T cells are the chief component of the immune system, which are targeted by different strategies aimed to increase their capacity against melanoma cells. To this end, reprogramming of T cells occurs by T cell centered manipulation, targeting the immunosuppressive tumor microenvironment or altering the whole patient. These are enabled by delivery of small molecules, functional monoclonal antibodies, different subunit vaccines, as well as living lymphocytes, native or genetically engineered. Current FDA-approved therapies are focused on direct T cell manipulation, such as immune checkpoint inhibitors blocking CTLA-4 and/or PD-1, which paves the way for an effective immunotherapy backbone available for combination with other modalities. Here we review the biology and clinical developments that enable melanoma immunotherapy today and in the future.

Original languageEnglish
Pages (from-to)104-124
Number of pages21
JournalAdvanced Drug Delivery Reviews
Volume141
DOIs
StatePublished - 15 Feb 2019

Funding

FundersFunder number
Haya and Nehemia Lemelbaum
Henry and Susan Samueli Foundation
Novartis
Israel Science Foundation15/1925

    Keywords

    • Adoptive cell transfer therapy
    • Immune checkpoints
    • Immunosuppressive microenvironment
    • Immunotherapy
    • PD-1
    • T cells
    • Vaccine

    Fingerprint

    Dive into the research topics of 'Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy'. Together they form a unique fingerprint.

    Cite this